{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011797","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.355462+00:00","generated_at":"2026-05-31T10:05:13.299509+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi","bullets":["Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.","Offering of 12.5M shares at $4.00 each for $50M gross proceeds; led by Sanofi ($30M) with Perceptive Advisors.","Cash and equivalents $100.0M as of June 30, 2024; believes funded into Q2 2026 with $285M potential J&J milestones.","Phase 2 AQUAx2 for xerostomia enrolling; FDA aligned on pivotal trial design. AAV-GAD for Parkinson's results expected Q4 2024.","UK ILAP designation for AAV-AIPL1 in LCA4; all 11 treated blind children gained visual acuity. Riboswitch platform data later 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011797","json":"https://secwatch.observer/filing/0001558370-24-011797.json","markdown":"https://secwatch.observer/filing/0001558370-24-011797.md","text":"https://secwatch.observer/filing/0001558370-24-011797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/0001558370-24-011797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/mgtx-20240812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:13.299509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}